ODTX Odyssey Therapeutics, Inc.
Fundamentals / CIK 0001882782 / USDOdyssey Therapeutics, Inc. reported $438.1M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ODTX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$326.0M Total debt: $23.48M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $99K | $959K | $1.92M |
| Research & Development | $42.12M | $36.23M | $32.32M | $26.32M | $30.23M | $38.77M |
| Total Operating Expenses | $56.67M | $55.47M | $39.78M | $38.35M | $42.88M | $41.08M |
| Operating Income | -$56.67M | -$55.47M | -$39.78M | -$38.25M | -$41.92M | -$39.16M |
| EBITDA | -$55.66M | -$54.43M | -$38.61M | -$37.07M | -$40.65M | -$37.86M |
| Interest Income | $3.86M | $2.83M | $1.71M | $2.20M | $872K | $1.16M |
| Interest Expense | $12K | $20K | $10K | $1.0K | $2.0K | $2.0K |
| Income Before Tax | -$53.01M | -$52.80M | -$38.20M | -$35.52M | -$41.20M | -$38.30M |
| Income Tax Expense | $49K | -$8.0K | $63K | -$56K | $30K | $140K |
| Net Income | -$53.06M | -$52.79M | -$38.26M | -$35.46M | -$41.23M | -$38.44M |
| Basic EPS | -$1.10 | -$1.74 | -$6.77 | -$7.78 | -$29.54 | -$39.37 |
| Diluted EPS | -$1.10 | -$1.74 | -$6.77 | -$7.78 | -$29.54 | -$39.37 |
| Basic Shares Outstanding | 48.0M | 30.3M | 5.7M | 4.6M | 1.4M | 976.1K |
| Diluted Shares Outstanding | 48.0M | 30.3M | 5.7M | 4.6M | 1.4M | 976.1K |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $80.64M | $82.03M | $35.72M | $41.69M |
| Short-Term Investments | $245.4M | $228.5M | $140.0M | $139.7M |
| Cash & Short-Term Investments | $326.0M | $310.6M | $175.7M | $181.4M |
| Accounts Receivable, Net | $0 | $0 | $0 | $0 |
| Total Current Assets | $337.8M | $321.5M | $185.1M | $190.7M |
| Property, Plant & Equipment, Net | $4.63M | $4.88M | $6.56M | $7.21M |
| Goodwill | $14.12M | $14.10M | $14.07M | $14.33M |
| Intangible Assets | $0 | $86K | $160K | $262K |
| Long-Term Investments | $60.99M | $122.5M | $0 | $35.20M |
| Other Non-Current Assets | $4.43M | $3.79M | $5.26M | $3.33M |
| Total Non-Current Assets | $100.3M | $162.4M | $43.97M | $79.13M |
| Total Assets | $438.1M | $483.9M | $229.1M | $269.8M |
| Accounts Payable | $8.26M | $7.67M | $8.22M | $7.87M |
| Total Current Liabilities | $26.10M | $28.30M | $22.21M | $26.48M |
| Total Non-Current Liabilities | $36.23M | $34.33M | $27.00M | $28.03M |
| Total Liabilities | $62.33M | $62.63M | $49.21M | $54.51M |
| Total Debt (incl. Leases) | $23.48M | $24.82M | $26.13M | $27.11M |
| Common Stock | $5.0K | $5.0K | $0 | $0 |
| Retained Earnings | -$712.2M | -$659.2M | -$606.4M | -$568.1M |
| Accumulated Other Comp. Income | -$985K | -$505K | -$147K | $245K |
| Total Stockholders' Equity | $375.8M | $421.2M | -$523.7M | -$488.3M |
| Total Equity | $375.8M | $421.2M | -$523.7M | -$488.3M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$53.06M | -$52.79M | -$38.26M | -$35.46M | -$41.23M | -$38.44M |
| Depreciation & Amortization | $1.01M | $1.04M | $1.17M | $1.19M | $1.27M | $1.30M |
| Stock-Based Compensation | $7.94M | $5.67M | $2.59M | $4.89M | $3.70M | $2.99M |
| Change in Payables | $651K | -$797K | $484K | -$678K | $278K | $713K |
| Operating Cash Flow | -$41.54M | -$34.51M | -$41.03M | -$31.26M | -$34.26M | -$38.62M |
| Capital Expenditure | -$504K | -$186K | -$148K | -$48K | -$29K | -$927K |
| Free Cash Flow | -$42.05M | -$34.69M | -$41.18M | -$31.30M | -$34.29M | -$39.55M |
| Investing Cash Flow | $43.29M | -$211.4M | $34.80M | -$172.9M | $23.30M | $34.13M |
| Financing Cash Flow | -$3.18M | $292.2M | $484K | $90.78M | $118.7M | $200K |
| Net Change in Cash | -$1.39M | $46.31M | -$5.72M | -$113.5M | $108.1M | -$4.22M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 12.94x | 11.36x | 8.33x | -- | -- | -- |
| Quick Ratio | 12.49x | 10.98x | 7.91x | -- | -- | -- |
| Debt to Equity | 0.06x | 0.06x | -- | -- | -- | -- |
| Revenue Growth (YoY) | -100.0% | -100.0% | -100.0% | -- | -- | -- |